Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN

Key Points

• Abner Herrman & Brock LLC cut its Amgen stake by 24.1% in the second quarter, selling 2,680 shares and retaining 8,418 shares valued at approximately $3.05 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported strong quarterly results, with revenue rising 9.5% year over year to $10.05 billion and earnings of $6.29 per share, exceeding analyst expectations. Management set fiscal 2026 earnings guidance at $22.30–$23.50 per share.
• The company declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 payout and a 2.5% yield, while analyst sentiment remained mixed with a consensus “Hold” rating and a $370.07 price target.

Abner Herrman & Brock LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 24.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,418 shares of the medical research company's stock after selling 2,680 shares during the period. Abner Herrman & Brock LLC's holdings in Amgen were worth $3,048,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Anfield Capital Management LLC lifted its position in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after buying an additional 55 shares during the period. Tower View Wealth Management LLC raised its stake in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Amgen in the fourth quarter worth about $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 1.5%

NASDAQ:AMGN opened at $410.95 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40. The company has a market cap of $221.79 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 3.77 and a beta of 0.41. The company has a 50 day simple moving average of $362.77 and a two-hundred day simple moving average of $356.24.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. During the same period in the prior year, the firm earned $6.02 EPS. The company's revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.73 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Oppenheimer upped their target price on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a report on Wednesday. Cantor Fitzgerald restated a "neutral" rating and set a $350.00 price target on shares of Amgen in a research report on Monday, July 6th. Bank of America upped their price target on Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a research note on Wednesday. Truist Financial raised their price objective on Amgen from $340.00 to $362.00 and gave the company a "hold" rating in a research report on Wednesday. Finally, Sanford C. Bernstein upped their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $370.07.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source